Palvella Therapeutics stock
PVLANASDAQPalvella Therapeutics, Inc., HealthcareISIN US6979471090
43Score 43 out of 100, Weak
Price and trend
84 / 100
Price history
+88% in one yearThe chart shows daily closes over 2 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 18% above it.
Normal: the price is neither overheated nor sold off (RSI 65).
The price is 13% below its 52-week high. Largest decline in 2 years: 31% (March 2025 to April 2025).
Chart figures for advanced users
- SMA 50$143.62
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$130.09
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)65
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$76.43
- The lowest closing price of the last twelve months.
- Resistance$175.92
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Palvella Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $2.24B, is number 115 of 296 companies in its industry on MEQIRI.
- MEQIRI Score 43 out of 100 (Weak): rank 510 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $57.98M, financial debt $633K.Stability 54
Weaknesses
- Loss-makingLoss of $41.72M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 84% a year over the last 12 months.Stability 54
- Negative free cash flowFree cash flow −$25.01M over the last 12 months.Fundamentals 17
Its standout strengths are momentum and technical analysis, while fundamentals and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net 0%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 30 Mar 2027in 138 days
- Last reported
- 5 Nov 2026EPS reported −$1.70 (expected −$1.78)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$6.57+0.4%
- Revenue
- $26.67K0.0%
- Earnings per share
- −$8.29+1.2%
- Revenue
- $23.57M−7.5%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +10.0%Planned launch sales force expanded to about 40 reps and 2026 cash spend rises modestly to $85 million to $95 million; more capital than originally expected is still planned at launch.
“We have also increased our planned sales force at launch to approximately 40 sales reps, at the upper end of our prior guidance.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $11.24M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Goin KathleenSale
21 Oct 2026, Chief Operating Officer
- Shares
- 4,313
- Price
- $124.58
- Value
- $537,307
- Jenkins George MSale
14 Oct 2026, Board
- Shares
- 7,174
- Price
- $123.49
- Value
- $885,914
- Jenkins George MSale
13 Oct 2026, Board
- Shares
- 7,174
- Price
- $130.36
- Value
- $935,232
Show 10 more
- Jenkins George MSale
12 Oct 2026, Board
- Shares
- 13,152
- Price
- $133.69
- Value
- $1.76M
- Goin KathleenSale
16 Sept 2026, Chief Operating Officer
- Shares
- 4,302
- Price
- $152.24
- Value
- $654,923
- Jenkins George MSale
15 Sept 2026, Board
- Shares
- 1,777
- Price
- $150.14
- Value
- $266,806
- Jenkins George MSale
14 Sept 2026, Board
- Shares
- 13,352
- Price
- $151.96
- Value
- $2.03M
- Jenkins George MSale
11 Sept 2026, Board
- Shares
- 12,371
- Price
- $151.28
- Value
- $1.87M
- Kiritsy Christopher PSale
2 Sept 2026, Board
- Shares
- 313
- Price
- $157.00
- Value
- $49,141
- Goin KathleenSale
19 Aug 2026, Chief Operating Officer
- Shares
- 4,302
- Price
- $152.21
- Value
- $654,791
- Goin KathleenSale
15 Jul 2026, Chief Operating Officer
- Shares
- 4,302
- Price
- $149.28
- Value
- $642,191
- Goin KathleenSale
17 Jun 2026, Chief Operating Officer
- Shares
- 4,302
- Price
- $110.73
- Value
- $476,373
- Goin KathleenSale
20 May 2026, Chief Operating Officer
- Shares
- 4,302
- Price
- $110.56
- Value
- $475,631
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Palvella Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 43
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Beam TherapeuticsBEAM $2.67B41
- NewAmsterdam PharmaNAMS $2.48B35
- Zealand PharmaZEAL.CO $2.42B59
- PharvarisPHVS $2.4B44
- Celldex TherapeuticsCLDX $2.37B36
- Trevi TherapeuticsTRVI $2.37B41
- BiohavenBHVN $2.29B43
- Replimune GroupREPL $2.29B43
ETFs that hold Palvella Therapeutics
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Harbor Health Care UCITS ETF AccW311 | 0.58% | 0.89% | €11.61M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.07% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.07% | 0.30% | €4.22B |
Show 5 more
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.48B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.02% | 0.45% | €1.53B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.35% | €434.1M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €175.89M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.00% | 0.30% | €944.34M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 12 Dec 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.